奥沙利铂联合氟尿嘧啶及吡柔比星在肝动脉化疗栓塞治疗中晚期肝癌中的应用及护理干预  

Nursing Intervention and Application of Oxaliplatin Combined with Fluorouracil and Pirarubicin in the Treatment of Middle and Late Stage of Liver Cancer Using Hepatic Arterial Chemoembolization

作　　者：赵俊燕[1] 鲁燕[2] 刘晓雅[1] ZHAO Jun-yan;LU Yan;LIU Xiao-ya(Osteopathy Department Ⅰ,Henan Province Hospital of TCM,Zhengzhou 450000,China;Venous Catheterization Room,Henan Province Hospital of TCM,Zhengzhou 450000,China)

机构地区：[1]河南省中医院骨病一科,郑州450000 [2]河南省中医院静脉置管室,郑州450000

出　　处：《中国合理用药探索》2021年第4期80-84,共5页Chinese Journal of Rational Drug Use

摘　　要：目的:研究奥沙利铂^(+)氟尿嘧啶^(+)吡柔比星运用于肝动脉化疗栓塞治疗中的价值及护理干预效果。方法:选择2018年5月~2020年5月本院收治的120例中晚期肝癌患者作为研究对象,依据随机双盲法分成研究组和对照组,各60例。对照组给予肝动脉栓塞治疗,研究组在对照组基础上灌注奥沙利铂^(+)氟尿嘧啶^(+)吡柔比星治疗,两组均给予针对性护理干预。比较两组临床疗效、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、血清指标[E-钙黏蛋白(EC)、甲胎蛋白(AFP)、内皮抑素(ES)、血管内皮生长因子(VEGF)]、不良反应及健康调查简表(SF-36)评分。结果:研究组治疗总有效率(93.33%)高于对照组(80.00%,P<0.05)。干预前,两组CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)、EC、AFP、ES、VEGF、SF-36评分比较无统计学差异(P>0.05);干预后,研究组各指标均优于对照组(P<0.05)。干预期间,两组不良反应发生率比较无统计学差异(P>0.05)。结论:奥沙利铂^(+)氟尿嘧啶^(+)吡柔比星运用于肝动脉化疗栓塞治疗中晚期肝癌中效果突出,同时配以针对性护理干预,可有效增强患者自身免疫力,促进相应血清指标恢复,减少严重不良反应发生,提升生存质量,值得推广。Objective:To study the value and nursing intervention effect of oxaliplatin,fluorouracil and pirarubicin in the treatment of hepatic artery chemoembolization.Methods:120 middle and late stage of liver cancer patients treated from May 2018 to May 2020 in our hospital were selected as research subjects.According to random double-blind method,patients were assigned to research group and control group,60 cases in each group.The control group took the hepatic arterial chemoembolization.On the basis of the control group,the research group took additional oxaliplatin,fluorouracil and pirarubicin.The specific nursing interventions were performed to patients in both groups.Clinical effects,immune function indicators[CD3^(+),CD4^(+),CD8^(+) and CD4^(+)/CD8^(+)],serum indicators[E-cadherin(EC),alpha fetoprotein(AFP),endostatin(ES),vascular endothelial growth factor(VEGF)],adverse reactions and the MOS 36-item short from health survey(SF-36)scores were appraised.Results:Total treatment effective rate in the research group(93.33%)was higher than that of the control group(80.00%,P<0.05).Before intervention,CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+),EC,AFP,ES,VEGF levels and SF-36 scores were not significantly different between two groups(P>0.05).After intervention,related indicators in the research group were better than those of the control group(P<0.05).During intervention,adverse event rate was not significantly different between the two groups(P>0.05).Conclusion:The combination of oxaliplatin,fluorouracil and pirarubicin showed outstanding effects in the hepatic arterial chemoembolization for treating middle and late stage of liver cancer patients.Combining with specific nursing interventions,this treatment regime can effectively improve the immune competence,promote the serum index recovery,avoid the serious adverse reactions and increase the life quality.It is worthy of promotion.

关 键 词：护理干预 奥沙利铂 肝动脉化疗栓塞 氟尿嘧啶 吡柔比星 

分 类 号：R972.6[医药卫生—药品]